Results 221 to 230 of about 126,534 (277)

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami   +16 more
wiley   +1 more source

History of glucagon-like peptide-1 receptor agonists

open access: yesPharmacological Research
Radwan Darwish   +2 more
doaj   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen   +7 more
wiley   +1 more source

An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller   +7 more
wiley   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay   +19 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.

open access: yesJAMA Netw Open
Hsiao FC   +7 more
europepmc   +1 more source

Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost‐effectiveness modelling study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti‐obesity drug, is very effective, but wider use is limited due to high costs.
Sai Rahul Ponnana   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy